Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ian Schofield

Edinburgh, U.K
Ian Schofield has been writing on issues affecting the pharmaceutical and biotech industry since the mid-1980s, specialising in EU and global policy and regulatory affairs.  As well as writing, editing and commissioning articles for Pharma Intelligence, Ian works for the Ask the Analyst service, providing tailor-made answers to questions posed directly by clients. He has a degree in modern languages from the University of Bath. Outside the realm of work, Ian plays guitar in a traditional music group and also enjoys a touch of cycling and gardening. He lives by the seaside about three miles from the centre of Edinburgh.
Advertisement
Set Alert for Articles By Ian Schofield

Latest From Ian Schofield

Yet Another Call For Views On What Brexit Means For Pharma, Regulation & Health

Another inquiry investigation into the consequences of Brexit in the life sciences area has been launched, this time by the House of Commons health committee. Stakeholders are asked to comment on issues like the impact on the regulation of medicines and medical devices, how to ensure continued access to medicines, and whether transitional arrangements will be needed.

Brexit Regulation

EMA’s Future Home: Assessment Of Bids Nears Completion Amid Growing Staff Concerns

Sept. 30 is the date by which the European Commission must complete its assessment of member states’ bids to host the European Medicines Agency after Brexit. The agency has again highlighted the pressures it is under as a result of the relocation, and the situation has worsened after some LGBT staff members expressed concern about their rights in certain potential host countries in eastern Europe.

Brexit Regulation

Problems With Alternative Levothyroxine In France Force Merck To Switch Back To Original

French patients who have experienced adverse reactions to a new formulation of Merck KGaA’s hypothyroidism drug Levothyrox are to be given temporary access to the original formulation, pending the availability of other brands of levothyroxine. Merck says the vast majority of patients have had no problems with the new version.

Drug Safety France

Australia Sees Surge In Level 3 Audits For Active Implantables

Australian regulators completed more Level 2 compulsory audits of applications to include class III and active implantable medical devices on the Australian Register of Therapeutic Goods in 2016-17.

Australia Approvals

Australia Sees Decline In Generic Filings, Rise in Extensions And ADR Reports

New drug submissions to the Australian TGA remained at the same level in 2016-17 as in the previous year, while the number of generic filings fell significantly. Extension of indications applications were up noticeably, as were adverse drug reaction reports for medicines and vaccines.

Approvals Generic Drugs

CHMP OKs First EU Biosimilar Herceptin, And Another Version Of Humira

Samsung Bioepis’s Ontruzant is set to be the first biosimilar version of Roche’s Herceptin on the EU market after getting the all-clear from the EMA’s CHMP on Sept. 15. The committee has also OKd another version of AbbVie’s Humira, this time from Boehringer Ingelheim.

Approvals Biosimilars
See All
Advertisement
UsernamePublicRestriction

Register